Medicare Enrolled
Dr. Lijo John, MD
Student in an Organized Health Care Education/Training Program · Longview, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. John from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. John? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. John
Dr. Lijo John is a student in an organized health care education/training program in Longview, TX, with 16 years in practice. Based on federal Medicare data, Dr. John performed 126,443 Medicare services across 4,996 unique beneficiaries.
Between the years covered by Open Payments, Dr. John received a total of $4,201 from 26 pharmaceutical and/or device companies across 70 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in student in an organized health care education/training program. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. John is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice▲ Top 0% volume in TX$ $4,201 industry payments
Medicare Practice Summary
Medicare Utilization ↗126,443
Medicare services
Top 0% in TX for student in an organized health care education/training program
4,996
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,903 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 36,720 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 21,585 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 13,200 | $43 | $137 |
| Contrast dye for imaging (iodine-based) | 9,945 | $0 | $3 |
| Nivolumab injection (Opdivo) | 9,760 | $24 | $76 |
| Paclitaxel chemotherapy injection | 7,986 | $0 | $8 |
| Iron sucrose injection (Venofer) | 6,700 | $0 | $2 |
| Oxaliplatin chemotherapy injection | 6,100 | $0 | $33 |
| Dexamethasone injection (steroid) | 1,544 | $0 | $1 |
| Blood draw (venipuncture) | 1,268 | $8 | $20 |
| Comprehensive metabolic blood panel | 1,135 | $10 | $64 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,120 | $22 | $155 |
| Complete blood count (CBC) with differential | 1,113 | $8 | $36 |
| Injection, granisetron hydrochloride, 100 mcg | 500 | $0 | $24 |
| Office visit, established patient (30-39 min) | 487 | $91 | $368 |
| Anti-nausea injection (Aloxi/palonosetron) | 440 | $1 | $114 |
| Injection, carboplatin, 50 mg | 348 | $2 | $300 |
| Lactate dehydrogenase (enzyme) level | 347 | $6 | $31 |
| Injection, fluorouracil, 500 mg | 343 | $2 | $13 |
| Office visit, established patient (20-29 min) | 311 | $62 | $250 |
| Administration of chemotherapy into vein, 1 hour or less | 307 | $98 | $707 |
| Office visit, established patient, complex (40-54 min) | 258 | $132 | $496 |
| Ferritin level test (iron stores) | 227 | $13 | $60 |
| Iron binding capacity test | 227 | $9 | $35 |
| Iron level test | 226 | $6 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 192 | $22 | $157 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 179 | $54 | $211 |
| Injection of additional new drug or substance into vein | 164 | $11 | $108 |
| Magnesium level test | 159 | $7 | $29 |
| Injection, zoledronic acid, 1 mg | 154 | $7 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 150 | $47 | $313 |
| Drug injection, under skin or into muscle | 147 | $10 | $96 |
| Reticulated (young) platelet measurement | 145 | $35 | $143 |
| Folic acid level test | 140 | $14 | $73 |
| Microscopic examination for white blood cells with manual cell count | 139 | $4 | $22 |
| Complete blood count (CBC), automated | 139 | $6 | $34 |
| Vitamin B-12 level test | 138 | $15 | $76 |
| Phosphate level test | 136 | $5 | $24 |
| Thyroid stimulating hormone (TSH) test | 132 | $16 | $80 |
| Injection, cisplatin, powder or solution, 10 mg | 125 | $2 | $94 |
| Administration of additional new drug or substance into vein, 1 hour or less | 117 | $48 | $344 |
| Administration of chemotherapy into vein, each additional hour | 100 | $21 | $161 |
| Ct scan of chest with contrast | 98 | $57 | $821 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 84 | $20 | $128 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 80 | $90 | $657 |
| Irrigation of implanted venous access drug delivery device | 79 | $18 | $114 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 76 | $71 | $70 |
| Injection, diphenhydramine hcl, up to 50 mg | 73 | $1 | $7 |
| PSA test (prostate cancer screening) | 72 | $18 | $94 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 72 | $134 | $3,675 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 68 | $337 | $1,722 |
| New patient office visit (45-59 min) | 66 | $115 | $565 |
| Infusion, normal saline solution , 1000 cc | 62 | $2 | $19 |
| CT scan of abdomen and pelvis with contrast | 59 | $166 | $1,067 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 59 | $1,109 | $4,802 |
| Hospital follow-up visit, moderate complexity | 59 | $58 | $247 |
| Immunoglobulin level test | 57 | $9 | $56 |
| Thyroxine (thyroid chemical), total | 54 | $7 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 50 | $15 | $100 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 49 | $272 | $2,762 |
| CT scan of chest, without contrast | 47 | $43 | $686 |
| Unclassified drugs | 47 | $1 | $8 |
| Injection of drug or substance into vein | 42 | $27 | $247 |
| Injection, magnesium sulfate, per 500 mg | 42 | $1 | $6 |
| Carcinoembryonic antigen (cea) protein level | 41 | $19 | $99 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 37 | $121 | $500 |
| Ct scan of abdomen and pelvis without contrast | 32 | $79 | $560 |
| Infusion into a vein for hydration, each additional hour | 29 | $10 | $75 |
| Initial hospital admission, moderate complexity | 29 | $100 | $470 |
| Administration of additional new drug or substance into vein using push technique | 28 | $41 | $289 |
| Red blood count automated, with additional calculations | 25 | $5 | $26 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $25 | $145 |
| New patient office visit, complex (60-74 min) | 23 | $156 | $709 |
| Nuclear medicine study whole body with ct scan | 21 | $1,109 | $4,929 |
| Drawing of blood for a medical problem | 21 | $49 | $264 |
| Infusion into a vein for hydration, 31-60 minutes | 20 | $25 | $256 |
| Initial hospital admission, high complexity | 20 | $133 | $694 |
| Stool analysis for blood, by fecal hemoglobin determination by immunoassay | 17 | $16 | $72 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $133 | $523 |
| Hospital follow-up visit, high complexity | 12 | $91 | $357 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
29.5% high complexity
64.3% medium
6.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,201
Total received (2018-2024)
Avg $700/year across 6 years
Top 9% in TX for student in an organized health care education/training program
26
Companies
70
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,714 (64.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,198 (28.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$289 (6.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$399
2023$3,455
2022$136
2021$134
2019$64
2018$12
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$2,759
GlaxoSmithKline, LLC.
$180
Janssen Biotech, Inc.
$144
Pharmacyclics LLC, An AbbVie Company
$135
AstraZeneca Pharmaceuticals LP
$112
E.R. Squibb & Sons, L.L.C.
$104
Myriad Genetic Laboratories, Inc.
$100
Novartis Pharmaceuticals Corporation
$97
Bayer Healthcare Pharmaceuticals Inc.
$77
EMD Serono, Inc.
$58
ABBVIE INC.
$49
Daiichi Sankyo Inc.
$48
Takeda Pharmaceuticals U.S.A., Inc.
$45
Celgene Corporation
$36
Lilly USA, LLC
$35
Seagen Inc.
$32
PFIZER INC.
$28
Incyte Corporation
$25
GENZYME CORPORATION
$24
Amgen Inc.
$20
MorphoSys, US Inc.
$18
Astellas Pharma US Inc
$17
CTI BioPharma Corp.
$17
Sun Pharmaceutical Industries Inc.
$15
Seattle Genetics, Inc.
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 73.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · BAVENCIO · BLENREP · CALQUENCE · DARZALEX · EPKINLY · Enhertu · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · KISQALI · Kyprolis · LIBTAYO · LUTATHERA · MONJUVI · MYRISK · NINLARO · Nubeqa · OJJAARA · OPDIVO · Odomzo · PADCEV · PLUVICTO · PROMACTA · Pomalyst · REBLOZYL · SARCLISA · SHINGRIX · Stivarga · VERZENIO · Vonjo · XALKORI · Xospata
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (65%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 9% for student in an organized health care education/training program in TX.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Student in an Organized Health Care Education/Training Programs within 10 mi
65
Per 100K population
52.1
County median income
$64,809
Nearest hospital
CHRISTUS GOOD SHEPHERD MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. John is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and high industry engagement (consulting-driven, top 9%), with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. John experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. John performed 36,720 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. John receive payments from pharmaceutical companies?
Yes. Dr. John received a total of $4,201 from 26 companies across 70 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. John's costs compare to other student in an organized health care education/training programs in Longview?
Dr. John's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. John) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Student in an Organized Health Care Education/Training Programs in Longview
Browse student in an organized health care education/training programs in Longview ranked by procedure volume and transparency data.
Highest volume
Top Student in an Organized Health Care Education/Training Programs in TX
Student in an Organized Health Care Education/Training Programs ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Student in an Organized Health Care Education/Training Programs in TX
Which TX student in an organized health care education/training programs receive the most from drug and device companies.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc..
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology